Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Guggenheim reaffirmed their buy rating on shares of Veracyte (NASDAQ:VCYT – Free Report) in a report published on Tuesday morning,Benzinga reports. The firm currently has a $45.00 price objective on ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

The trial of three men accused in the theft or sale of an 18-carat gold toilet that was a pricey piece of satirical art is ...

The post Inside Bitter Real Estate Battle Over Late Guggenheim Exec's $400 Million Estate—as His Former Mansion Is Listed for ...

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...

Guggenheim reaffirmed their buy rating on shares of CyberArk Software (NASDAQ:CYBR – Free Report) in a research note issued ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

In Miami Beach, Fla., a waterfront estate asking $88 million has elements inspired by Manhattan’s Guggenheim Museum.